News Stories

The 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia released today, focused on addressing evaluation, management, and monitoring of individuals living with dyslipidemia, including high blood cholesterol, elevated triglycerides, and elevated lipoprotein(a) [Lp(a)].

The National Lipid Association (NLA) today announced the publication of a new meta-analysis evaluating the impact of low-density lipoprotein cholesterol (LDL-C) lowering on major adverse cardiovascular events (MACE) in primary prevention populations. The study synthesizes data from randomized trials of both statin and non-statin therapies and updates a landmark 2012 analysis conducted by the Cholesterol Treatment Trialists’ Collaboration (CTTC).

The mission of the National Lipid Association (NLA) is “to enhance the science and practice of lipidology and promote optimal cardiometabolic health.” The NLA leadership acknowledges the publication of the 2025-2030 Dietary Guidelines for Americans (DGAs), which are used to inform dietary guidance and nutrition policies for the general population.